Month: April 2026

In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration MiniMeCP2 is functionally comparable to full-length MeCP2 across molecular and biochemical functions, with both proteins exhibiting comparable, stable expression in neuronal cells Data further validate the selection of scAAV9 and miniMeCP2 in the TSHA-102 construct and provide translational support for the Part A REVEAL Phase 1/2 clinical data in patients with Rett syndrome DALLAS, April 27, 2026 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies...

Oral and poster presentations highlight progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 11-15, 2026 in Boston, MA. “We’re excited to return to ASGCT with a broad and compelling set of presentations that highlight the depth of Lexeo’s science and continued progress across our pipeline, from encouraging cardiac and neurologic data in Friedreich...

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics’ first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly. “The European Commission’s decision to approve Palsonify reflects the strength of the clinical data and marks a pivotal step toward bringing this...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, April 27, 2026 (GLOBE NEWSWIRE) — Traction Uranium Corp. (CSE: TRAC) (OTC: TRCTF) (FRA: Z1K) (the “Company” or “Traction”) is pleased to announce that it has closed its previously announced non-brokered private placement of units (the “Units”) of the Company (the “Offering”). The Offering was completed under the listed issuer financing exemption (the “LIFE Exemption”) under Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. Pursuant to the Offering, the Company issued an aggregate of 3,000,000 Units at a price of $0.30 per Unit for aggregate gross proceeds of $900,000. Each Unit...

Vancouver, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) — Apogee Minerals Ltd. (“Apogee” or the “Company” or the “Optionee”) (TSXV: APMI) announces a non-brokered private placement financing of up to 55,000,000 units at a price of $0.05 per unit (the “Units”) for gross proceeds of up to $2,750,000 (the “Offering”). The financing is now fully subscribed for and the Company plans to close shortly. Each Unit will consist of one common share and one transferrable common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to purchase one additional common share in the capital of the Company at $0.075 per share for four (4) years from the date of issue. The use of proceeds from the Offering will be used for general working capital and exploration expenditures in Saskatchewan. This financing is subject...

BOULDER, Colo., April 27, 2026 (GLOBE NEWSWIRE) — Auddia Inc. (NASDAQ: AUUD) (NASDAQ: AUUDW) (“Auddia” or the “Company”), a technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio, today announced the closing of its previously announced best efforts public offering of an aggregate of 5,084,743 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,084,743 shares of common stock (the “Warrants”), at a combined public offering price of $2.36 per share (or per common stock equivalent in lieu thereof) and accompanying Warrant. The Warrants have an exercise price of $2.36 per share, are exercisable immediately upon issuance and expire upon the earlier of: (i) the consummation of the transactions...

WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the financial markets tomorrow, April 28, 2026. Aclaris will host a webcast and conference call with slides tomorrow morning at 8:30 AM EST to discuss these updates. The live and archived webcast will be available on the Events page of the Company’s website: https://investor.aclaristx.com/events. The webcast will be archived on the same page for...